Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,705.00
Bid: 1,650.00
Ask: 1,710.00
Change: 0.00 (0.00%)
Spread: 60.00 (3.636%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,705.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: FTSE 100 underwhelms as stocks jump after US CPI

Tue, 14th Nov 2023 17:04

(Alliance News) - European equities jumped in the wake of a cooler-than-expected US inflation reading, which took some sting out of a recent hawkish reassessment of the Federal Reserve interest rate outlook.

A hold by the US central bank next month is now completely priced in. According to the CME FedWatch Tool, there was a 15% chance of a hike a day ago, as investors digested hawkish comments from Fed Chair Jerome Powell from last week.

The FTSE 100 index rose by 14.64 points, 0.2%, at 7,440.47. It represents a solid gain, though massively underperforming peers.

The FTSE 250 shot up 622.48 points, 3.5%, at 18,536.13, and the AIM All-Share rose 8.85 points, 1.3%, at 709.72.

The Cboe UK 100 rose 0.3% at 743.54, the Cboe UK 250 jumped 3.8% at 16,064.08, and the Cboe Small Companies surged 1.8% at 13,192.44.

In European equities on Tuesday, the CAC 40 in Paris surged 1.4%, while the DAX 40 in Frankfurt shot up 1.8%.

According to the Bureau of Labor Statistics, the consumer price index rose by 3.2% in October from a year before, slowing from a 3.7% increase in September. The inflation rate had been expected to cool only to 3.3%, according to FXStreet-cited market consensus.

The rate of inflation is now closer to the Fed's 2% target.

The core annual inflation rate eased to 4.0% in October from 4.1% in September, a pace it had been expected to maintain last month.

The Fed earlier in November left the federal funds rate range unmoved at 5.25% to 5.50%, a 22-year-high, and where it has been since July.

But hiking expectations picked up slightly after Chair Jerome Powell struck a hawkish tone last week.

Powell said Thursday that the Fed was prepared to hike again if needed.

The Fed chair's words gave the dollar some support towards the back end of last week, but the greenback was on the back foot on Tuesday, even prior to the inflation data.

Sterling was quoted at USD1.2475 late Tuesday afternoon, higher than USD1.2264 at the London equities close on Monday. The pound was trading around a two-month-high.

The euro traded at USD1.0855 on Tuesday afternoon, up from USD1.0696 at the London equities close on Monday. Against the yen, the dollar was quoted at JPY150.85, down versus JPY151.59.

Gold was quoted at USD1,964.57 an ounce late Tuesday, up from USD1,945.38 on Monday. The precious metal has an inverse relationship with the dollar.

In New York, the Dow Jones Industrial Average was up 1.7%, the S&P 500 surged 2.1% and the Nasdaq Composite jumped 2.3%, with tech shares benefitting from the cooler US inflation reading.

Interest rate sensitive stocks in London also shone. Warehouse investor Segro and housebuilder Taylor Wimpey added 6.4% and 8.1% as the property excelled in the wake of the US data, as rate worries eased.

It was not only in foreign currency and equity markets where moves were dramatic post-US data. The yield on the US 10-year Treasury eased markedly to as low as 4.43% following the data, from a high of 4.70% on Monday.

The stronger sterling meant the FTSE 100 was unable to rise as strongly as European peers. London's blue-chip index is stacked with international earners.

Index heavyweights such as GSK, Shell and Unilever fell 1.7%, 1.4% and 0.9%.

A hefty 5.5% fall for Vodafone also kept a lid on the FTSE 100. The Newbury, Berkshire-based telecommunications provider said pretax profit in the six months to September 30 dived to EUR550 million from EUR1.69 billion a year prior. Revenue fell 4.3% to EUR21.94 billion from EUR22.93 billion.

It swung to a net loss of EUR155 million, from profit of EUR1.20 billion.

At the other end of the FTSE 100, DCC surged 12%. It said revenue and profit both fell in the latest half year but declared an increased dividend.

The Dublin-based sales, marketing and support services firm said pretax profit for the six months that ended on September 30 was GBP129.7 million, down from GBP312.3 million the previous year.

Revenue fell 11% to GBP9.62 billion from GBP10.84 billion. This was mainly due to lower average commodity prices, which caused DCC Energy revenue to decrease 9.7% to GBP2.3 billion.

DCC nonetheless declared an interim dividend of 63.04 pence per share, up 5.0% from 60.04 pence the year before.

Elementis rose 5.2%. It set out a lofty margin target and said it plans "above market revenue growth by 2026".

The speciality chemicals firm, hosting a capital markets day in the wake of receiving calls from some shareholders for an immediate sale of the company, also said it is eyeing cost cuts.

London-based Elementis is looking for an adjusted operating profit margin above 19% as part of its 2026 financial targets. It achieved an adjusted operating profit margin of 13.6% in 2022, rising from 12.4% in 2021.

"The 19% target operating margin will be achieved through our growth and efficiency programmes based on current market conditions, whilst a modest recovery in the demand environment could see the margin rise above this level," Elementis said.

It is also targeting delivering "USD90 million of above market revenue growth by 2026".

The capital markets day comes after Elementis has faced shareholder scrutiny recently.

In September, Franklin Mutual Advisors, an investment advisory firm parented by Franklin Templeton, published an open letter requesting that the Elementis board "initiate an immediate sale of the company".

The targets announced by Elementis on Tuesday were not enough to win over Franklin.

"The proposed targets are based on multiple assumptions several years into the future. The current management has been in charge for nearly eight years and consistently disappointed shareholders with value destruction and missed targets. We continue to believe that the company should start a formal sales process to maximize shareholder value," Franklin Mutual Series Senior Vice President-Portfolio Manager Steve Raineri said.

AIM-listed Horizonte Minerals tumbled 48%. It said it will scale back construction activities at its Araguaia nickel asset in Brazil to manage its resources and funds.

Horizonte said it will be advancing only critical workstreams, as it attempts to save cash as it tries to secure more funding.

The Araguaia project had total liquidity sources of USD169 million at November 10, which it explained "should provide sufficient working capital to around mid-December 2023 unless there are positive outcomes from conversations with suppliers, other cash preserving measures, or other financing solutions".

It added that financing discussions with shareholders and lenders continue.

Brent oil was trading at USD83.42 a barrel at the time of the European equities, rising from USD82.39 a day prior.

Wednesday's economic calendar has China retail sales data and a Japanese gross domestic product reading overnight. There is UK inflation data at 0700 GMT, eurozone industrial production at 1000 GMT and a US producer price index at 1330 GMT.

The local corporate calendar has half-year results from utility firm SSE and pub company Fuller, Smith & Turner.

By Eric Cunha, Alliance News news editor

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

More News
1 May 2024 19:39

Bird flu testing shows more dairy products are safe, US FDA says

CHICAGO, May 1 (Reuters) - Preliminary results of tests on additional dairy products show that pasteurization inactivates the bird flu virus, the U.S. Food and Drug Administration said on Wednesday.

Read more
1 May 2024 17:31

UK's FTSE 100 slips ahead of Fed outcome, energy stocks weigh

FTSE 100 down 0.3%, FTSE 250 off 0.2%

*

Read more
1 May 2024 16:56

LONDON MARKET CLOSE: FTSE 100 down ahead of US interest rate decision

(Alliance News) - Stock prices in London closed mostly in the red on Wednesday, as investors eye the latest interest rate decision from the US Federal Reserve this evening.

Read more
1 May 2024 16:42

London close: Stocks fall ahead of US Fed decision

(Sharecast News) - London markets closed lower on Wednesday, as investors digested the latest UK manufacturing data and anticipated an impending policy announcement from the US Federal Reserve.

Read more
1 May 2024 11:55

LONDON MARKET MIDDAY: FTSE 100 treads water as Fed takes centre-stage

(Alliance News) - London's FTSE 100 traded off session highs heading into Wednesday afternoon, as some pre-Federal Reserve decision nerves kicked in.

Read more
1 May 2024 10:54

GSK raises profit outlook on strong vaccine, HIV drug sales

FY profit forecast raised to 8-10%

*

Read more
1 May 2024 08:57

LONDON MARKET OPEN: FTSE 100 shakes off New York slump before Fed

(Alliance News) - Stock prices in London opened mixed on Wednesday, with the FTSE 100 brushing off some pre-Federal Reserve decision trepidation to record an early rise, while the dollar climbed on the expectation that Jerome Powell will sound hawkish in his press conference later.

Read more
1 May 2024 08:50

TOP NEWS: GSK expects momentum to continue after strong first quarter

(Alliance News) - GSK PLC on Wednesday raised its annual earnings forecast, and said it expects sales growth at the top-end of guidance, after a "strong" start to the year.

Read more
1 May 2024 07:46

LONDON BRIEFING: GSK ups outlook; Next first-quarter beats forecast

(Alliance News) - Equities in London are called to open flat on Wednesday, ahead of the latest Federal Reserve interest rate decision, while a host of financial markets in mainland Europe and beyond are closed for public holidays.

Read more
1 May 2024 07:36

GSK lifts annual guidance on strong virus treatment sales

(Sharecast News) - UK pharmaceutical giant GSK lifted annual profits guidance on Wednesday, as it pinned its hopes on demand for its respiratory virus and shingles treatments.

Read more
30 Apr 2024 23:46

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 22:39

First trial over Zantac cancer claims set to begin in Chicago

April 30 (Reuters) - The first trial over claims that blockbuster heartburn drug Zantac, once sold by GSK and other companies, causes cancer is set to begin this week in Chicago.

Read more
30 Apr 2024 13:51

Sensodyne maker Haleon to shut UK factory with loss of 435 jobs

(Alliance News) - More than 400 jobs are to be axed at Sensodyne toothpaste and Advil painkillers firm Haleon PLC as the group revealed plans to shut its only manufacturing site in the UK.

Read more
30 Apr 2024 12:22

Sensodyne-maker Haleon to shut UK plant, 435 jobs to go

April 30 (Reuters) - Haleon, the world's largest standalone consumer healthcare firm, will shut its UK production site which makes Sensodyne toothpastes by 2026, leading to 435 job losses, a spokesperson said on Tuesday.

Read more
25 Apr 2024 15:53

GlaxoSmithKline sues Pfizer and BioNTech over Covid-19 vaccine technology

April 25 (Reuters) - GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies' blockbuster COVID-19 vaccines.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.